TRAVERE THERAPEUTICS, INC. — Revenue by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/f9ee4c2e-e555-47c8-ad96-7d141959de56/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $490.7M | 2025-01-01 – 2025-12-31 | evidence 0001438533-26-000014 |
| FY 2024 | $233.2M | 2024-01-01 – 2024-12-31 | evidence 0001438533-25-000010 |
| FY 2023 | $145.2M | 2023-01-01 – 2023-12-31 | evidence 0001438533-24-000005 |
| FY 2022 | $109.5M | 2022-01-01 – 2022-12-31 | evidence 0001438533-24-000005 |
| FY 2021 | $131.8M | 2021-01-01 – 2021-12-31 | evidence 0001438533-24-000005 |
| FY 2020 | $198.3M | 2020-01-01 – 2020-12-31 | evidence 0001438533-21-000008 |
| FY 2019 | $175.3M | 2019-01-01 – 2019-12-31 | evidence 0001438533-20-000004 |
| FY 2018 | $164.2M | 2018-01-01 – 2018-12-31 | evidence 0001438533-19-000003 |
| FY 2017 | $154.9M | 2017-01-01 – 2017-12-31 | evidence 0001438533-19-000003 |
| FY 2016 | $133.6M | 2016-01-01 – 2016-12-31 | evidence 0001438533-19-000003 |
| FY 2015 | $99.9M | 2015-01-01 – 2015-12-31 | evidence 0001628280-16-011857 |
| FY 2014 | $28.2M | 2014-01-01 – 2014-12-31 | evidence 0001628280-16-011857 |
| FY 2013 | $0 | 2013-01-01 – 2013-12-31 | evidence 0001628280-16-011857 |
| FY 2011 | $0 | 2011-03-02 – 2012-02-29 | evidence 0001225279-12-000073 |
| FY 2010 | $0 | 2010-03-01 – 2011-02-28 | evidence 0001225279-12-000073 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
TRAVERE THERAPEUTICS, INC. — all facts · Net Income · Operating Income